Back to mobile site

Mizuho on Adverum Biotechnologies (ADVM): 'Seeing Upside at Current Valuation'

November 17, 2025 5:51 AM EST Send to a Friend
Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $5.50 price target on Adverum Biotechnologies (NASDAQ: ADVM)The analyst comments "ADVM ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login